The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Teplova N.V.

Pirogov Russian National Research Medical University

A couple more?

Authors:

Teplova N.V.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2025;(11): 38‑43

Read: 118 times

Contact the author
Table of contents

To cite this article:

Teplova NV. A couple more? Non Nocere. New Therapeutic Journal. 2025;(11):38‑43. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

The problem of polypharmacy in a comorbid patient. A pharmacologist’s perspective.

Authors:

Teplova N.V.

Pirogov Russian National Research Medical University

Close metadata

References:

  1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012 Jul 7;380(9836):37-43.  https://doi.org/10.1016/S0140-6736(12)60240-2
  2. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012 Jan;11(1):83-94.  https://doi.org/10.1517/14740338.2012.631910
  3. Oganov R.G., Denisov I.N., Simanenkov V.I., et al. Comorbidities in practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017;16(6):5-56. (In Russ.) https://doi.org/10.15829/1728-8800-2017-6-5-56
  4. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011 Sep;10(4):430-439.  https://doi.org/10.1016/j.arr.2011.03.003
  5. Clinical Pharmacology according to Goodman and Gilman / H. Akil et al.; edited by A.G. Gilman; editors: J. Hardman, L. Limberd; translation from English edited by N.N. Alipov. – Moscow: Praktika, 2006. – 1648 p. 
  6. Berdnikova N.G. The importance of using ciprofloxacin in clinical practice. RMJ. 2007;5:351. 
  7. Tatro D.S. Drug Interaction Facts. – Wolters Kluwer Health, 2008. – 1889 p. 
  8. Belousov Yu.B. Clinical pharmacology: national guidelines / edited by Yu.B. Belousov, V.G. Kukes, V.K. Lepakhin, V.I. Petrov. – Moscow: GEOTAR-Media, 2014. – 976 p. 
  9. State Register of Medicines. Medicines. Digoxin. Registration Certificate: LP-No. (003719)-(RG-RU) dated November 17, 2023. Accessed: September 7, 2025. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1b2ed833-b647-449d-bcc7-b10f108a5729
  10. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013 Apr;138(1):103-141.  https://doi.org/10.1016/j.pharmthera.2012.12.007
  11. Guengerich FP. Cytochrome P450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1-17.  https://doi.org/10.1146/annurev.pharmtox.39.1.1
  12. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6-13.  https://doi.org/10.1038/sj.tpj.6500285
  13. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol. 2005;45:477-494.  https://doi.org/10.1146/annurev.pharmtox.45.120403.095821
  14. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913-958.  https://doi.org/10.2165/00003088-200241120-00002
  15. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008 Jan 22;51(3):256-260.  https://doi.org/10.1016/j.jacc.2007.06.064
  16. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-581.  https://doi.org/10.1016/j.clpt.2006.09.003
  17. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos. 1996 Apr;24(4):422-428. 
  18. O’Reilly RA. Interaction of sodium warfarin and rifampin. Studies in man. Ann Intern Med. 1974 Sep;81(3):337-340.  https://doi.org/10.7326/0003-4819-81-3-337
  19. Cardiology: national guidelines / edited by E.V. Shlyakhto. – Moscow: GEOTAR-Media, 2015. – 800 p. 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.